semaglutide + pembrolizumab + bortezomib + rituximab

This is a **combination therapy** consisting of four distinct pharmaceutical agents: semaglutide, pembrolizumab (Keytruda), bortezomib, and rituximab. Each has unique mechanisms of action and primary indications: - **Semaglutide** is a glucagon-like peptide 1 receptor agonist used primarily for type 2 diabetes and obesity. - **Pembrolizumab** (Keytruda) is an immune checkpoint inhibitor targeting PD-1, used in the treatment of multiple cancers. - **Bortezomib** is a reversible proteasome inhibitor indicated for multiple myeloma and mantle cell lymphoma. - **Rituximab** is a chimeric monoclonal antibody against CD20, primarily used for B-cell malignancies and some autoimmune disorders. There are no standard clinical contexts in which all four drugs are used together, and such a combination would be highly experimental. However, combinations of bortezomib and rituximab are studied in hematologic malignancies, and pembrolizumab may be added in some investigational immuno-oncology regimens.

Brand names

KeytrudaOzempicWegovyRybelsusVelcadeRituxan

Other names

semaglutide + Keytruda + bortezomib + rituximab-Shandong Cancer Hospital and Institute-breast cancerpembrolizumabsemaglutidebortezomibrituximab